Skip to main content
. Author manuscript; available in PMC: 2020 Jul 30.
Published in final edited form as: Kidney Int. 2019 Jun 11;96(5):1185–1194. doi: 10.1016/j.kint.2019.05.019

Figure 3. Multivariable hazard ratios for all-cause mortality and heart failure hospitalization for those randomized to enalapril or placebo according to magnitude of decline at 2-weeks (left), and 6-weeks (right).

Figure 3.

Placebo, 0% eGFR held as reference point (represented by diamond). Filled circles represent points where hazard ratio for all-cause mortality is significant (p<0.05) compared to the reference point. eGFR indicates estimated glomerular filtration rate, calculated using adjusted serum creatinine and CKD-EPI equation. Number of patients at each follow-up time point were 6245 at 2-weeks, and 6055 at 6-weeks. Models adjusted for age, sex, race, baseline kidney function, previous myocardial infarction, smoking, NYHA functional class, diastolic blood pressure, hematocrit, potassium, and trial.